Dyno Therapeutics has been named Startup of the Year by Xconomy, an award that recognizes the most innovative new company with a focus on those advancing creative solutions to the challenges of biology, to break onto the scene this year.

“We are incredibly honored to be selected as Xconomy’s Startup of the Year and recognized for our pioneering approach to gene therapy,” said Eric Kelsic, PhD, chief executive officer of Dyno Therapeutics. “Key to Dyno’s rapid ascent has been our systematic focus on solving gene therapy’s biggest challenge, the efficient, safe and precise gene delivery to target tissues. Just as essential to our success is our diverse team of the best problem solvers who are driving cutting-edge science toward improving patient health.”

Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative high-throughput in vivo experiments to gene therapy. The company’s proprietary CapsidMap™ platform rapidly discovers and systematically optimizes Adeno-Associated Virus (AAV) capsid vectors that significantly outperform current approaches for in vivo gene delivery, thereby expanding the range of diseases treatable with gene therapies.Dyno recently came out of stealth and earlier this year, signed deals valued in excess of $2 billion with gene therapy leaders Novartis and Sarepta.

Since 2017, the mission of Xconomy’s annual awards programs has been to provide the industry a moment to pause, recognize, and honor the very best the life sciences has to offer – the people, companies, and organizations that challenge the status quo and never accept what works as good enough.